---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-050771"
form_type: "8-K"
ticker: "MRKR"
cik: "0001094038"
company_name: "Marker Therapeutics, Inc."
filed_at: "2025-05-20T23:59:59+00:00"
generated_at: "2026-05-20T23:34:45.642485+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Marker Therapeutics: lymphodepletion improves MT-601 cell expansion; enrollment surging

## Summary
- Phase 1 APOLLO study data: TCR sequencing shows MT-601 clones expanded/persisted at higher levels with lymphodepletion.
- Prior data (Dec 2024): 7/9 patients (78%) objective response, 4 complete responses (44.4%); no DLTs or ICANS.
- In first 5 months of 2025, enrolled and manufactured product for more patients than in all of 2024.
- Company expects clinical data readout from APOLLO study later this year.
- MT-601 targets lymphoma patients who relapsed after anti-CD19 CAR-T or for whom CAR-T is not an option.

## SEC filing metadata
- accession: 0001104659-25-050771
- form_type: 8-K
- ticker: MRKR
- cik: 0001094038
- company_name: Marker Therapeutics, Inc.
- filed_at: 2025-05-20T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1094038/000110465925050771/0001104659-25-050771-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1094038/000110465925050771/tm2515620d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-050771
- JSON: https://secwatch.observer/filing/0001104659-25-050771.json
- Plain text: https://secwatch.observer/filing/0001104659-25-050771.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.